SCHEMBL9930972

SCHEMBL9930972

COC(=O)c1cc(C(N)C(=O)OC(C)(C)C)ccc1C(F)F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.35
CFTR P13569 1/20 0.35
HSD17B10 Q99714 5/20 0.33
KDM4E B2RXH2 4/20 0.33
ALDH1A1 P00352 4/20 0.33
HPGD P15428 4/20 0.33
GAA P10253 3/20 0.33
MAPT P10636 2/20 0.33
ALOX15 P16050 1/20 0.33
TSHR P16473 1/20 0.33
APP P05067 1/20 0.33
ATR Q13535 1/20 0.33
SLC7A5 Q01650 1/20 0.33
TDP1 Q9NUW8 3/20 0.33
MEN1 O00255 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
KMT2A Q03164 2/20 0.33
CYP2D6 P10635 1/20 0.33
GRM8 O00222 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6629348 0.85 APP (0.42) DPP4CFTRHSD17B10KDM4EALDH1A1
SCHEMBL6141363 0.83 KDM4E (0.48) CFTRHSD17B10KDM4EALDH1A1HPGD
SCHEMBL12231302 0.82 APP (0.42) DPP4CFTRHSD17B10KDM4EALDH1A1
SCHEMBL27333282 0.81 KDM4E (0.43) CFTRHSD17B10KDM4EALDH1A1HPGD
SCHEMBL27338051 0.80 ATR (0.33) CFTRHSD17B10KDM4EALDH1A1HPGD
SCHEMBL29036907 0.80 SLC6A4 (0.37) CFTRTSHRCYP2C19CYP2D6SLC6A4
SCHEMBL1830457 0.80 ATR (0.41) CFTRHSD17B10KDM4EALDH1A1HPGD
SCHEMBL3651078 0.78 SIRT6 (0.45) KDM4EALDH1A1HPGDMAPTTDP1
SCHEMBL3654152 0.76 VCAM1 (0.38) ALDH1A1HPGDGAAMAPTTDP1
SCHEMBL2569650 0.76 MAPT (0.45) DPP4KDM4EALDH1A1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655335-A1 NOVEL IMIDAZOLE-2-BENZAMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF OSTEOARTHRITIS Eli Lilly and Company (US) 2013-10-30 EP disclosed
US-8252831-B2 Imidazole-2-benzamide compounds useful for the treatment of osteoarthritis ELI LILLY AND COMPANY (US) 2012-08-28 US disclosed
WO-2012087771-A1 NOVEL IMIDAZOLE-2-BENZAMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF OSTEOARTHRITIS ELI LILLY AND COMPANY (US) 2012-06-28 WO disclosed
US-20120157506-A1 Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis ELI LILLY AND COMPANY (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157506-A1 Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis ARG2, HDAC6, COL2A1 DPP4 1758/4885CFTR 2233/4885HSD17B10 3030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.